GOVERNMENT OF INDIA
MINISTRY OF AYURVEDA, YOGA & NATUROPATHY,
UNANI, SIDDHA AND HOMOEOPATHY
(AYUSH)

LOK SABHA
UNSTARRED QUESTION NO. 1014
TO BE ANSWERED ON 18th SEPTEMBER, 2020

AYURVEDIC DRUGS AND PROTOCOL FOR COVID-19

1014. SHRI SUDHAKAR TUKARAM SHRANGARE:
SHRI SUNIL KUMAR SINGH:
PROF.SAUGATA RAY:
SHRI SUMEDHANAND SARASWATI:

Will the Minister of AYURVEA, YOGA AND NATUROPATHY, UNANI,
SIDDHA AND HOMOEOPATHY (AYUSH) be pleased to state:

(a) whether any proposal on Ayurvedic Drug and Protocol developed for Covid 19 by a team
of eminent Ayurvedic physicians for clinical trials is under consideration of the Government;

(b) if so, the details thereof alongwith the reasons for inordinate delay in granting permission
for clinical trials; and

(c) the remedial steps taken by the Government in this regard?

ANSWER

THE MINISTER OF HEALTH AND FAMILY WELFARE
(DR. HARSH VARDHAN)

(a)& (b): Ministry of AYUSH has formed an Inter-disciplinary AYUSH R&D Task
Force. Task Force has formulated and designed clinical research protocols for prophylactic
studies and add-on interventions in COVID-19 positive cases through thorough review and
consultative process of experts of high repute from different organizations across the country
for studying four different interventions viz. Ashwagandha, Yashtimadhu, Guduchi + Pippali
and a poly herbal formulation (AYUSH-64). Ayush Sanjivani mobile app developed by
Ministry of AYUSH has also been launched to generate data on acceptance and usage of
AYUSH advocacies and measures among the population and its impact in prevention of
COVID-19 targeting 05 million population. All these studies are at various stages of
conduction.

Further, a total of 247 proposals of Ayurveda interventions have been received under
modified Extra Mural research (EMR) Scheme for SARS CoV-2 infection and COVID-19
disease. Out of 247 proposals, 21 research proposals recommended by competent authority
on Ayurveda for SARS/COVID cases have been approved for funding.

(c): In view of (a) & (b) above, the question does not arise.